MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors.

Epigenetics Molecular biology Molecular mechanism of gene regulation

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 08 11 2023
revised: 11 01 2024
accepted: 06 02 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

Emerging data suggest a significant cross-talk between metabolic and epigenetic programs. However, the relationship between the mechanistic target of rapamycin (mTOR), which is a pivotal metabolic regulator, and epigenetic modifications remains poorly understood. Our results show that mTORC1 activation caused by the abrogation of its negative regulator tuberous sclerosis complex 2 (TSC2) coincides with increased levels of the histone modification H3K27me3 but not H3K4me3 or H3K9me3. This selective H3K27me3 induction was mediated via 4E-BP-dependent increase in EZH2 protein levels. Surprisingly, mTOR inhibition also selectively induced H3K27me3. This was independent of TSC2, and was paralleled by reduced EZH2 and increased EZH1 protein levels. Notably, the ability of mTOR inhibitors to induce H3K27me3 levels was positively correlated with their anti-proliferative effects. Collectively, our findings demonstrate that both activation and inhibition of mTOR selectively increase H3K27me3 by distinct mechanisms, whereby the induction of H3K27me3 may potentiate the anti-proliferative effects of mTOR inhibitors.

Identifiants

pubmed: 38433910
doi: 10.1016/j.isci.2024.109188
pii: S2589-0042(24)00409-7
pmc: PMC10904987
doi:

Types de publication

Journal Article

Langues

eng

Pagination

109188

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

HaEun Kim (H)

Department of Experimental Medicine, McGill University, Montreal, QC H3A 0G4, Canada.
Lady Davis Institute, SMBD JGH, McGill University, Montreal, QC H3T 1E2, Canada.

Benjamin Lebeau (B)

Department of Experimental Medicine, McGill University, Montreal, QC H3A 0G4, Canada.
Lady Davis Institute, SMBD JGH, McGill University, Montreal, QC H3T 1E2, Canada.
School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.

David Papadopoli (D)

Lady Davis Institute, SMBD JGH, McGill University, Montreal, QC H3T 1E2, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.

Predrag Jovanovic (P)

Department of Experimental Medicine, McGill University, Montreal, QC H3A 0G4, Canada.
Lady Davis Institute, SMBD JGH, McGill University, Montreal, QC H3T 1E2, Canada.

Mariana Russo (M)

Goodman Cancer Research Centre, Montréal, QC H3A 1A3, Canada.

Daina Avizonis (D)

Goodman Cancer Research Centre, Montréal, QC H3A 1A3, Canada.

Masahiro Morita (M)

Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

Farzaneh Afzali (F)

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.

Josie Ursini-Siegel (J)

Department of Experimental Medicine, McGill University, Montreal, QC H3A 0G4, Canada.
Lady Davis Institute, SMBD JGH, McGill University, Montreal, QC H3T 1E2, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Department of Biochemistry, McGill University, Montreal, QC H3A 0G4, Canada.

Lynne-Marie Postovit (LM)

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.

Michael Witcher (M)

Department of Experimental Medicine, McGill University, Montreal, QC H3A 0G4, Canada.
Lady Davis Institute, SMBD JGH, McGill University, Montreal, QC H3T 1E2, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.

Ivan Topisirovic (I)

Department of Experimental Medicine, McGill University, Montreal, QC H3A 0G4, Canada.
Lady Davis Institute, SMBD JGH, McGill University, Montreal, QC H3T 1E2, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Department of Biochemistry, McGill University, Montreal, QC H3A 0G4, Canada.

Classifications MeSH